search

Active clinical trials for "DiGeorge Syndrome"

Results 41-47 of 47

Thymus Transplantation Safety-Efficacy

Complete DiGeorge AnomalyDiGeorge Syndrome2 more

Complete DiGeorge anomaly (cDGA) is a disorder in which there is no thymus function. With no thymus function, bone marrow stem cells do not develop into educated T cells, which fight infection. Without successful treatment, patients with cDGA must remain in reverse isolation to prevent infection and subsequent death. Cultured thymus tissue with and without immunosuppression (drugs given before and after implantation) has resulted in the development of good T cell function in subjects with complete DiGeorge anomaly. This expanded access study continues cultured thymus tissue safety and efficacy research for the treatment of complete DiGeorge anomaly. Eligible participants receive cultured thymus tissue. Immune function testing is continued for one year post-implantation.

Approved for marketing23 enrollment criteria

Prenatal Examination of Deletion 22q11 Syndrome : Thymic Dysgenesis THYMI Study

22q11 Deletion Syndrome Di George Syndrome

22q11.2 microdeletion seems the prenatally under-diagnosed . Indeed , there is a mismatch between the series on the heart rate of 22q11.2 antenatal 84% against 30% in the adult series despite a perinatal mortality of 16% suggesting opportunities for improvement in the prenatal diagnosis of fetus with a microdeletion 22q11.2 , especially without heart disease

Completed4 enrollment criteria

Expanded Noninvasive Genomic Medical Assessment: The Enigma Study

Down SyndromeEdwards Syndrome6 more

In January 2007, the American Congress of Obstetricians and Gynecologists (ACOG) revised its guidelines that now recommend physicians are ethically obligated to fully inform all pregnant women that screening for fetal chromosomal abnormalities including biochemical screening tests and invasive procedures such as CVS or amniocentesis is available, regardless of age. Further, it is entirely up to the patient to decide whether or not she wishes to be screened for fetal chromosomal abnormalities without judgment from the physician. Noninvasive laboratory-developed tests (LDTs) that detect an abnormal amount of maternal and fetal DNA in an expectant mother's blood sample (known as circulating cell-free DNA) are now available. These LDTs have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although LDTs to date have not been subject to U.S. FDA regulation, certification of the laboratory is required under the Clinical Laboratory Improvement Amendments (CLIA) to ensure the quality and validity of the test. To sample collection study will obtain whole blood specimens from pregnant subjects to be used for development of prenatal assays to assist in the screening for fetal genetic abnormalities, infectious and other diseases, and blood group typing through detection of circulating cell-free DNA extracted from maternal plasma.

Completed13 enrollment criteria

Genetic Modifiers for 22q11.2 Syndrome

22q11.2 Deletion Syndrome

The purpose of the project is the determination of how the deletion of DNA from chromosome 22 at the q11.2 band causes the phenotypes observed in velo-cardio-facial syndrome (VCFS). In other words, the purpose remains genotype-to-phenotype matching. Current methods includes the use of whole genome chips and microarray analysis. Blood samples are collected for DNA from every patient who consents from the VCFS Center at Upstate Medical University. They are examined for phenotypic features consistent with our typical clinical evaluation. The information from these examinations will be entered anonymously into a database. Genomic information is then matched to clinical phenotype with appropriate statistical method applied.

Completed2 enrollment criteria

Genetics and Psychopathology in the 22q11 Deletion Syndrome

Chromosome 22q11.2 Deletion Syndrome

The purposes of this study are to: study the nature and longitudinal course of psychiatric symptoms in children with the 22q11.2 deletion syndrome and identify genes that contribute to the occurrence of these symptoms.

Unknown status2 enrollment criteria

Immunologic Evaluation in Patients With DiGeorge Syndrome or Velocardiofacial Syndrome

DiGeorge SyndromeShprintzen Syndrome4 more

OBJECTIVES: I. Determine the pattern of immunologic reconstitution in patients with T-cell compromise due to DiGeorge syndrome or velocardiofacial syndrome. II. Determine any correlation between immunologic function in these patients and chromosome 22 deletion breakpoints. III. Determine presence of sustained immunologic compromise in older patients.

Unknown status1 enrollment criteria

Whole Blood Specimen Collection From Pregnant Subjects

Down SyndromeEdwards Syndrome5 more

To obtain whole blood specimens from pregnant subjects to be used for research and development and clinical validation studies of prenatal assays.

Unknown status9 enrollment criteria
1...45

Need Help? Contact our team!


We'll reach out to this number within 24 hrs